Once-weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Patients with HIV Taking Dolutegravir-Based Antiretroviral Therapy: a Phase 1/2 Trial.Kelly E. Dooley,Radojka M. Savic,Akshay Gupte,Mark A. Marzinke,Nan Zhang,Vinodh A. Edward,Lisa Wolf,Modulakgotla Sebe,Morongwe Likoti, Mark J. Fyvie, Innocent Shibambo,Trevor Beattie,Richard E. Chaisson,Gavin J. ChurchyardThe Lancet HIV（2020）引用 37|浏览48暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
